Alain Eid, MD
Critical Care Medicine · Colorado Springs, CONPI 1639174352
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by GSK at 44.7% of the total. Reporting peaked in 2020 at $8,346 and has fallen 91.5% since, to $709 in 2025. Among critical care medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $46.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Intuitive Surgical$3K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$587
- Boehringer Ingelheim$574
- Bayer$511
- plus $4K from 39 others
Across 28 payments — averaging $3578.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$59K
- Janssen Research & Development, LLC$23K
- Astrazeneca UK Limited$18K
What the payments were for
- Speaking & faculty fees$7,20039%
- Travel & lodging$1481%
- Food & beverage$8,02243%
- Education$3,12317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$7,325
- Da Vinci Surgical System$3,252
- Inspire$114
How this compares
$18,493 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 46 | $1,017,981 |
| OpsumitMacitentan | 17 | $227,877 |
| AdempasRiociguat | 14 | $197,521 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 144 | $155,737 |
| Ambrisentan | 35 | $56,435 |
| Spiriva RespimatTiotropium Bromide | 37 | $26,383 |
| EliquisApixaban | 25 | $23,905 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $21,163 |
| Tadalafil | 26 | $19,095 |
| XareltoRivaroxaban | 15 | $14,243 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,573 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,374 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,929 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,022 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $587 | $1,245,85863 claims |
| BayerAdempas | $511 | $197,52114 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $8,259 | $167,310160 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $574 | $34,75749 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,150 | $28,09334 claims |
| PfizerEliquis | $135 | $23,90525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Colorado Springs
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
- Nitin GuptaLittleton$35K
- Paula McDermottLittleton$34K
- Jennifer Faber GerlingDenver$30K
- Jeffrey SippelAurora$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.